Pricing
  1. US-listed companies
  2. KYNTRA BIO, INC.
  3. Financials
  4. Common stock and paid-in capital

KYNTRA BIO, INC.【KYNB】

Market cap
$28.19M
P/E ratio
SummaryFinancials
Period EndCommon stock and paid-in capital (Million USD)YoY (%)
Dec 31, 20241,670+1.52%
Dec 31, 20231,645+6.66%
Dec 31, 20221,542+4.37%
Dec 31, 20211,477+5.47%
Dec 31, 20201,401+7.61%
Dec 31, 20191,302+6.05%
Dec 31, 20181,227+5.72%
Dec 31, 20171,161+182147.88%
Dec 31, 20161-99.89%
Dec 31, 2015587

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)